" class="no-js "lang="en-US"> Pfizer Initiates Study Exploring Coadministration of 20vPnC Vaccine Candidate - Medtech Alert
Wednesday, March 29, 2023

Breaking News

Coeptis Therapeutics Secures Exclusive Rights to Negotiate the Acquisition of Transformational Cell Therapy Platform SamaCare Partners with AmerisourceBergen to Offer Prior Authorization Platform to Specialty Practices Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia PharmaVentures Establishes an Office in Seoul to Enhance Access for South Korean Biotechs Genialis Raises $13M in Financing to Build Clinical Biomarkers that Predict Patient Response Pharmaron’s Liverpool UK Gene Therapy CDMO Commences Major Site Expansion Following UK Government Grant to Support £151m Investment Lantern Pharma Announces First Patient Dosed in Study for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer Transcenta’s Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer MIMETAS and Astellas Enter into Strategic Partnership
Pfizer Initiates Study Exploring Coadministration of 20vPnC Vaccine Candidate | Pharmtech Focus

May 24 2021

Pfizer Initiates Study Exploring Coadministration of 20vPnC Vaccine Candidate

Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA). The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines.

The trial will include 600 adults who will be recruited from the pivotal Phase 3 Pfizer-BioNTech COVID-19 Vaccine trial and will have received their second dose of the vaccine at least six months prior to entering the coadministration study. The participants are being randomized to one of three groups:

  • 20vPnC plus Pfizer-BioNTech COVID-19 Vaccine booster, which is a third dose of the Pfizer-BioNTech COVID-19 Vaccine
  • 20vPnC plus placebo 
  • Pfizer-BioNTech COVID-19 Vaccine booster plus placebo

Companies In This Post

BioNTech SE | Pharmtech Focus

BioNTech SE
Pfizer | Pharmtech Focus

Pfizer
  1. Coeptis Therapeutics Secures Exclusive Rights to Negotiate the Acquisition of Transformational Cell Therapy Platform

    Diseases

     Read more
  2. SamaCare Partners with AmerisourceBergen to Offer Prior Authorization Platform to Specialty Practices

    News

     Read more
  3. Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer

    Drug Development

     Read more
  4. BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia

    News

     Read more
  5. PharmaVentures Establishes an Office in Seoul to Enhance Access for South Korean Biotechs

    News

     Read more
More On